(Q36095135)

12 August 2017

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines (English)

1 reference

12 August 2017

12

Hanne Nøkleby

1 reference

12 August 2017

7

Audun Aase

1 reference

12 August 2017

8

Ingeborg S Aaberge

1 reference

12 August 2017

3

Philipp Oster

1 reference

12 August 2017

13

Einar Rosenqvist

1 reference

12 August 2017

1

Synne Sandbu

1 reference

12 August 2017

2

Berit Feiring

1 reference

12 August 2017

4

Oddveig S Helland

1 reference

12 August 2017

11

Sandrine Tilman

1 reference

12 August 2017

6

Lisbeth M Naess

1 reference

Anne-Cathrine Kristoffersen

12 August 2017

PMCID

2043307

series ordinal

9

object named as

Anne-Cathrine Kristoffersen

1 reference

12 August 2017

Hilde S W Bakke

5

1 reference

PMCID

2043307

12 August 2017

Kjersti M Rydland

series ordinal

10

1 reference

12 August 2017

18 July 2007

1 reference

Clinical and Vaccine Immunology

12 August 2017

1 reference

12 August 2017

14

1 reference

12 August 2017

9

1 reference

12 August 2017

1062-1069

1 reference

Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Meningococcal surrogates of protection--serum bactericidal antibody activity

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Immunologic response of man to group B meningococcal polysaccharide vaccines.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Outer membrane protein vesicle vaccines for meningococcal disease

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043307

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

23 September 2018

1 reference

12 December 2020

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

1 reference

12 December 2020

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine

1 reference

12 December 2020

The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic

1 reference

12 December 2020

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

12 December 2020

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile

1 reference

12 December 2020

Antibody-Induced Opsonophagocytosis of Serogroup B Meningococci Measured by Flow Cytometry

1 reference

12 December 2020

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs

1 reference

12 December 2020

Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine

1 reference

12 December 2020

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

12 December 2020

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control

1 reference

12 December 2020

Identifiers

DOI

10.1128/CVI.00094-07

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

PMCID

2043307